Abstract

Goal: The goal of this unique core will be to provide cost-effective high speed flow cytometry and related services to the Program Project members. Two major uses are anticipated: 1) rapid purification of high numbers of cells transfected with a fluorescent protein, typically for experiments involving multiple samples. The purified cells need to be >95% pure and will be used for biochemical, immunological, or short term cell culture assays. 2) rapid purification of murine hematopoietic stem cells and progenitor cells for subsequent infection with retroviruses containing an oncogene or signaling molecule. These cells are typically present in low numbers, and final purity needs to be 95-99%. They will be used either for in vitro cell culture assays (such as colony assays) or for re-injection in mice as part of a bone marrow transplant experiment. Sterile sorting is essential for both types of experiments.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
2P01DK050654-06
Application #
6583513
Study Section
Special Emphasis Panel (ZDK1)
Project Start
2002-08-01
Project End
2007-07-31
Budget Start
Budget End
Support Year
6
Fiscal Year
2002
Total Cost
Indirect Cost

  Institution

Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02115

  Publications

Weisberg, E; Ray, A; Barrett, R et al. (2010) Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia 24:2100-9
Weisberg, Ellen; Roesel, Johannes; Furet, Pascal et al. (2010) Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. Genes Cancer 1:1021-32
Weisberg, Ellen; Choi, Hwan Geun; Ray, Arghya et al. (2010) Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood 115:4206-16
Weisberg, E; Deng, X; Choi, H G et al. (2010) Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. Leukemia 24:1375-8
Weisberg, Ellen; Choi, Hwan Geun; Barrett, Rosemary et al. (2010) Discovery and characterization of novel mutant FLT3 kinase inhibitors. Mol Cancer Ther 9:2468-77
Moldovan, George-Lucian; Madhavan, Mahesh V; Mirchandani, Kanchan D et al. (2010) DNA polymerase POLN participates in cross-link repair and homologous recombination. Mol Cell Biol 30:1088-96
Weisberg, E; Sattler, M; Ray, A et al. (2010) Drug resistance in mutant FLT3-positive AML. Oncogene 29:5120-34
Jiang, Jingrui; Griffin, James D (2010) Wnt/?-catenin Pathway Modulates the Sensitivity of the Mutant FLT3 Receptor Kinase Inhibitors in a GSK-3? Dependent Manner. Genes Cancer 1:164-76
Kim, Jung Min; Parmar, Kalindi; Huang, Min et al. (2009) Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Dev Cell 16:314-20
Mercher, Thomas; Raffel, Glen D; Moore, Sandra A et al. (2009) The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. J Clin Invest 119:852-64

Showing the most recent 10 out of 111 publications